Intravenous Fosfomycin: The Underdog Player in the Treatment of Carbapenem-resistant Acinetobacter baumannii Infections

Clin Infect Dis. 2023 Dec 15;77(12):1736-1737. doi: 10.1093/cid/ciad435.

Authors

Maurizio Guastalegname¹, Enrico Maria Trecarichi¹, Alessandro Russo¹

Affiliation

¹ Department of Medical and Surgical Sciences, Infectious and Tropical Disease Unit, 'Magna Graecia' University of Catanzaro, Catanzaro, Italy.

PMID: 37477512
DOI: 10.1093/cid/ciad435

No abstract available

Publication types

Letter
Comment

MeSH terms

Acinetobacter baumannii*
Anti-Bacterial Agents / therapeutic use
Carbapenems / pharmacology
Carbapenems / therapeutic use
Fosfomycin* / therapeutic use
Humans
Microbial Sensitivity Tests

Substances

Fosfomycin
Anti-Bacterial Agents
Carbapenems